NFKB1 and cancer: However, gefitinib/Osimertinib treatment significantly reduced p65 expression in the nucleus and increased in the cytoplasm of sensitive HCC827 cells, suggesting that gefitinib/osimertinib resistance accelerates the progression of malignant tumors through NF-κB activation (Figure 5C).